Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration
- Cite this article as:
- Boiko, S.S., Ostrovskaya, R.U., Zherdev, V.P. et al. Bull Exp Biol Med (2000) 129: 359. doi:10.1007/BF02439270
- 72 Downloads
Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an umodified state.